In a recent conversation with Dr. Andy Beck, co-founder and CEO of PathAI, we had the opportunity to discuss PathExplore, an AI-driven platform that aims to transform the way tumor microenvironment (TME) analysis is conducted. Traditional methods such as manual pathology, multiplex immunofluorescence and single-cell omics often face limitations, including high costs or tissue consumption.…
PathAI presents data on using AI to aid liver research and NASH drug development
Pathology-focused AI company PathAI will present findings on the use of machine learning (ML) to enhance the scoring of nonalcoholic steatohepatitis (NASH) at the 2022 AASLD 2022 Liver Meeting. The AASLD 2022 Liver Meeting is Nov. 4–8 in Washington, D.C., where the company will share five presentations. Boston-based PathAI developed four of them with pharmaceutical collaborators. An…